Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study

Read this article on the Breast Cancer Research and Treatment website.

Publication Details
Blaes A, Beckwith H, Florea N, Hebbel R, Solovey A, Potter D, Yee D, Vogel R, Luepker R, Duprez D. Breast Cancer Research and Treatment, November 2017

Study Information
Vascular Assessment in Breast Cancer Survivors Taking Aromatase Inhibitors

The purpose of this study at the University of Minnesota is to learn more about the effect that aromatase inhibitors have on a postmenopausal woman’s heart and blood vessels. To study this, the researchers are analyzing the blood vessel elasticity and heart health of three groups: women with breast cancer who have been on an aromatase inhibitor (and are HER2-negative); women with triple negative breast cancer; and healthy women. The researchers wanted to enroll up to 50 volunteers from the Greater St. Paul, Minn., area and they enlisted the Love Research Army (LoveRA) to help support their recruitment efforts. The Call to Action for this study was sent to LoveRA members on May 7, 2014, and the researchers closed enrollment on Aug. 11, 2014. The LoveRA provided them with 95 women who were interested in enrolling in the study. Inhibitors will impair vascular relaxation and result in impaired endothelial function as compared to that of two patient populations: healthy postmenopausal women and those with triple negative breast cancer (TNBC) who do not receive aromatase inhibitors.

Love Research Army

We combat the disparities that exist in research by challenging the scientific community to launch studies that are as inclusive and diverse as the people that breast cancer affects.

En Español »